Celgene Co. (CELG) Shares Bought by Banced Corp
Banced Corp grew its stake in Celgene Co. (NASDAQ:CELG) by 27.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,247 shares of the biopharmaceutical company’s stock after acquiring an additional 1,145 shares during the period. Banced Corp’s holdings in Celgene were worth $548,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Thompson Davis & CO. Inc. raised its stake in shares of Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 43 shares during the last quarter. Arcadia Investment Management Corp MI raised its stake in shares of Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 400 shares during the last quarter. Robecosam AG bought a new stake in shares of Celgene during the third quarter worth approximately $114,000. Guidant Wealth Advisors bought a new stake in shares of Celgene during the third quarter worth approximately $119,000. Finally, Capital Bank & Trust Co raised its stake in shares of Celgene by 166.8% during the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 517 shares during the last quarter. 78.10% of the stock is owned by institutional investors.
Shares of Celgene Co. (NASDAQ:CELG) opened at $91.98 on Wednesday. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29. Celgene Co. has a 1 year low of $88.32 and a 1 year high of $147.17. The stock has a market cap of $69,190.00, a price-to-earnings ratio of 25.48, a price-to-earnings-growth ratio of 0.66 and a beta of 1.49.
In other news, insider Mark J. Alles purchased 3,260 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were purchased at an average cost of $91.90 per share, with a total value of $299,594.00. Following the completion of the transaction, the insider now owns 178,904 shares of the company’s stock, valued at approximately $16,441,277.60. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.95% of the company’s stock.
A number of equities research analysts recently weighed in on the stock. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price target for the company in a research note on Thursday, January 25th. Mizuho set a $128.00 price target on shares of Celgene and gave the stock a “buy” rating in a research note on Tuesday, December 26th. William Blair reissued an “outperform” rating on shares of Celgene in a research note on Friday, October 20th. BTIG Research reissued a “hold” rating on shares of Celgene in a research note on Tuesday, January 23rd. Finally, BidaskClub raised shares of Celgene from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. Celgene has a consensus rating of “Buy” and an average target price of $130.35.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.